Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis
Scleroderma Diagnostics and Therapeutics Market By Diagnostic Test Type (Blood Tests, Imaging Techniques, Skin Biopsy, Pulmonary Function Tests, and Electrocardiogram & Echocardiogram), By Indication (Systemic Scleroderma and Localized Scleroderma), By Drug Class (Prostacyclin Analogues, Endothelin Receptor Antagonists, Phosphodiesterase 5 Inhibitors – PHA, Immunosuppressors, Analgesics, Calcium Channel Blockers, and Others), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028
Published Date: 12-Apr-2022Healthcare
Category: Report Format : PDF
Report Code: ZMR-3321
Status : Published
The global scleroderma diagnostics and therapeutics market was approximately USD 2232.5 million in 2021 and is anticipated to reach nearly USD 4127.6 million by 2028, with a compound annual growth rate (CAGR) of about 9.2 percent over the forecast period.